Profluents open source AI CRISPR tool brings gene editing to the masses

0 12

By Matthew Griffin Enhanced Humans and Biotech 28th May 2024

WHY THIS MATTERS IN BRIEF

Open source changed the technology industry now imagine what everyone could do if they had open access to editing the human genome at scale …

Love the Exponential Future? Join our XPotential Community, future proof yourself with courses from XPotential University, read about exponential tech and trends, connect, watch a keynote, or browse my blog.

Artificial Intelligence (AI) enabled protein design company Profluent has leveraged AI to design an open-source gene editor called OpenCRISPR-1, demonstrating the technology can be used to create molecules with the power to edit human DNA. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology, developed more than a decade ago, allows scientists to modify DNA sequences within living organisms precisely. Potential applications range from treatments for genetic disorders to researching disease mechanisms.

Baltimore becomes the first US city to be watched from the air 24/7

The molecules it designs are fully synthetic and do not exist in nature, in contrast to previous technologies in gene editing, such as CRISPR-Cas9.

The company is open-sourcing OpenCRISPR-1 for free ethical research and commercial use and published the science behind the protein’s development in a preprint publication.

“Attempting to edit human DNA with an AI-designed biological system was a scientific moonshot,” Ali Madani, Profluent cofounder and CEO, said in a statement. “Our success points to a future where AI precisely designs what is needed to create a range of bespoke cures for disease.”

Promising anti-aging treatment that extends lifespans by a third heads for human trials

AI was at the heart of this achievement, with the company training Large Language Models (LLMs) on massive scale sequence and biological context. The Profluent team developed a database of 5.1 million Cas9-like proteins, and the AI model was trained on this database to create potential proteins for CRISPR use.

This enabled the LLM to create novel gene editors from scratch as it learned through examples found in nature. After narrowing down the results, they identified OpenCRISPR-1, a protein performing similarly to Cas9 but with far less impact on off-target sites. This makes it more precise and causes minimal damage to DNA.

The goal of open-sourcing OpenCRISPR-1 is to encourage the use of AI for ethical research and commercial use, particularly in developing medicines leveraging CRISPR.

A decade after the first person was cured of HIV, another is in remission

“We believe by doing so, we can help accelerate the pace of discovery and innovation in the field,” Madani said. “Our vision is to move biology from being constrained by what can be achieved in nature to being able to use AI to design new medicines precisely according to our needs.”

He added that the company intends to partner with cutting-edge research institutions and drug developers working across the drug development life cycle to enable CRISPR medicines to become available to a greater number of patients and for a greater number of disorders.

Gene-editing technologies, including SHERLOCK and DETECTR, are transforming digital diagnostics, enabling rapid detection of infectious diseases such as COVID-19.

New cancer therapy completely destroys advanced tumours in trials

Companies such as Atomwise, Deep Genomics and Valo are incorporating gene editing into drug discovery processes, revolutionizing treatment development.

Beyond gene editing, AI is powering everything from bone marrow analysis software to drug discovery and platforms to help pair patients with the right cancer-treatment drugs.

Matthew Griffin / About Author

Matthew Griffin, multi-award winning Futurist and named Futurist of the Year 2024, has been described as a "Walking encyclopaedia of the future" by NASA and a futurist polymath. One of the world's most renowned futurists and strategic foresight experts Matthew is the 15 times author of the blockbuster "Codex of the Future" series, and is the Founder and Futurist in Chief of the 311 Institute, a global Futures and Deep Futures advisory firm working across the next 50 years, XPotential University, the world's first free futures and foresight university, and the World Futures Forum which works with the United Nations to solve the worlds greatest challenges. Matthew is an in demand international keynote, acclaimed university lecturer and mentor, and host of the hit Fanatical Futurist podcast.

A rare talent in his past Matthew helped build and run several multi-billion dollar business units for Atos, Dell-EMC, and IBM, and his ability to identify, track, and explain the impacts of hundreds of emerging technologies and trends on global business, culture, and society has earned him a powerful reputation and a roster of clients that include royal households, world leaders, G7, G20, and G77+ governments, and many of the world's most respected brands including ABB, Accenture, Adidas, AON, ARM, BCG, Centrica, Citi Group, Coca Cola, Dentons, Deloitte, Disney, Dow, EY, KPMG, Lego, Legal & General, LinkedIn, Microsoft, PepsiCo, Qualcomm, RWE, Samsung, T-Mobile, UBS, VISA, and many others. He was also the only futurist invited to talk at the UN COP28 held in Dubai alongside world leaders.

Regularly featured in the global media including the AP, BBC, Bloomberg, CNBC, Discovery, Forbes, Khaleej Times, Telegraph, TIME, ViacomCBS, WIRED, and the WSJ, Matthews mission is to help organisations create a fair and sustainable future whose benefits are shared by everyone irrespective of their ability, background, or circumstances.